Literature DB >> 27837450

Subcellular Parkinson's Disease-Specific Alpha-Synuclein Species Show Altered Behavior in Neurodegeneration.

Rashed Abdullah1, Ketan S Patil1, Benjamin Rosen1, Ramavati Pal1, Shubhangi Prabhudesai1, Sungsu Lee1, Indranil Basak1, Esthelle Hoedt2,3, Peter Yang1, Keith Panick1, Hsin-Pin Ho4, Emmanuel Chang4, Charalampos Tzoulis5, Jan Petter Larsen6, Thomas A Neubert2,3, Guido Alves6, Simon G Møller7,8.   

Abstract

Parkinson's disease and other synucleinopathies are characterized by the presence of intra-neuronal protein aggregates enriched in the presynaptic protein α-synuclein. α-synuclein is considered an intrinsically disordered 14 kDa monomer, and although poorly understood, its transition to higher-order multimeric species may play central roles in healthy neurons and during Parkinson's disease pathogenesis. In this study, we demonstrate that α-synuclein exists as defined, subcellular-specific species that change characteristics in response to oxidative stress in neuroblastoma cells and in response to Parkinson's disease pathogenesis in human cerebellum and frontal cortex. We further show that the phosphorylation patterns of different α-synuclein species are subcellular specific and dependent on the oxidative environment. Using high-performance liquid chromatography and mass spectrometry, we identify a Parkinson's disease enriched, cytosolic ~36-kDa α-synuclein species which can be recapitulated in Parkinson's disease model neuroblastoma cells. The characterization of subcellular-specific α-synuclein features in neurodegeneration will allow for the identification of neurotoxic α-synuclein species, which represent prime targets to reduce α-synuclein pathogenicity.

Entities:  

Keywords:  Alpha-synuclein; Fractionation; Multimers; Oxidative stress; Parkinson’s disease

Mesh:

Year:  2016        PMID: 27837450     DOI: 10.1007/s12035-016-0266-8

Source DB:  PubMed          Journal:  Mol Neurobiol        ISSN: 0893-7648            Impact factor:   5.590


  56 in total

1.  PARK13 regulates PINK1 and subcellular relocation patterns under oxidative stress in neurons.

Authors:  Ketan S Patil; Indranil Basak; Sungsu Lee; Rashed Abdullah; Jan Petter Larsen; Simon Geir Møller
Journal:  J Neurosci Res       Date:  2014-05-02       Impact factor: 4.164

2.  Alpha-synuclein acts in the nucleus to inhibit histone acetylation and promote neurotoxicity.

Authors:  Eirene Kontopoulos; Jeffrey D Parvin; Mel B Feany
Journal:  Hum Mol Genet       Date:  2006-09-07       Impact factor: 6.150

3.  Membrane association and protein conformation of alpha-synuclein in intact neurons. Effect of Parkinson's disease-linked mutations.

Authors:  P J McLean; H Kawamata; S Ribich; B T Hyman
Journal:  J Biol Chem       Date:  2000-03-24       Impact factor: 5.157

4.  Phosphorylation of Ser-129 is the dominant pathological modification of alpha-synuclein in familial and sporadic Lewy body disease.

Authors:  John P Anderson; Donald E Walker; Jason M Goldstein; Rian de Laat; Kelly Banducci; Russell J Caccavello; Robin Barbour; Jiping Huang; Kristin Kling; Michael Lee; Linnea Diep; Pamela S Keim; Xiaofeng Shen; Tim Chataway; Michael G Schlossmacher; Peter Seubert; Dale Schenk; Sukanto Sinha; Wei Ping Gai; Tamie J Chilcote
Journal:  J Biol Chem       Date:  2006-07-17       Impact factor: 5.157

5.  Valproic acid is neuroprotective in the rotenone rat model of Parkinson's disease: involvement of alpha-synuclein.

Authors:  Barbara Monti; Valentina Gatta; Francesca Piretti; Simonetta S Raffaelli; Marco Virgili; Antonio Contestabile
Journal:  Neurotox Res       Date:  2009-07-21       Impact factor: 3.911

6.  PINK1/Parkin-mediated mitophagy is dependent on VDAC1 and p62/SQSTM1.

Authors:  Sven Geisler; Kira M Holmström; Diana Skujat; Fabienne C Fiesel; Oliver C Rothfuss; Philipp J Kahle; Wolfdieter Springer
Journal:  Nat Cell Biol       Date:  2010-01-24       Impact factor: 28.824

7.  Neutral red uptake assay for the estimation of cell viability/cytotoxicity.

Authors:  Guillermo Repetto; Ana del Peso; Jorge L Zurita
Journal:  Nat Protoc       Date:  2008       Impact factor: 13.491

8.  α-Synuclein occurs physiologically as a helically folded tetramer that resists aggregation.

Authors:  Tim Bartels; Joanna G Choi; Dennis J Selkoe
Journal:  Nature       Date:  2011-08-14       Impact factor: 49.962

Review 9.  Copper and copper proteins in Parkinson's disease.

Authors:  Sergio Montes; Susana Rivera-Mancia; Araceli Diaz-Ruiz; Luis Tristan-Lopez; Camilo Rios
Journal:  Oxid Med Cell Longev       Date:  2014-01-08       Impact factor: 6.543

10.  Mechanisms of hybrid oligomer formation in the pathogenesis of combined Alzheimer's and Parkinson's diseases.

Authors:  Igor F Tsigelny; Leslie Crews; Paula Desplats; Gideon M Shaked; Yuriy Sharikov; Hideya Mizuno; Brian Spencer; Edward Rockenstein; Margarita Trejo; Oleksandr Platoshyn; Jason X-J Yuan; Eliezer Masliah
Journal:  PLoS One       Date:  2008-09-04       Impact factor: 3.240

View more
  3 in total

1.  Binding Stability of Antibody-α-Synuclein Complexes Predicts the Protective Efficacy of Anti-α-synuclein Antibodies.

Authors:  Matthias Höllerhage; Andreas Wolff; Tasnim Chakroun; Valentin Evsyukov; Linghan Duan; Oscar Wing-Ho Chua; Qilin Tang; Thomas Koeglsperger; Günter U Höglinger
Journal:  Mol Neurobiol       Date:  2022-04-22       Impact factor: 5.682

Review 2.  The delta-opioid receptor and Parkinson's disease.

Authors:  Jin-Zhong Huang; Yi Ren; Yuan Xu; Tao Chen; Terry C Xia; Zhuo-Ri Li; Jian-Nong Zhao; Fei Hua; Shi-Ying Sheng; Ying Xia
Journal:  CNS Neurosci Ther       Date:  2018-08-03       Impact factor: 5.243

3.  Protective efficacy of phosphodiesterase-1 inhibition against alpha-synuclein toxicity revealed by compound screening in LUHMES cells.

Authors:  Matthias Höllerhage; Claudia Moebius; Johannes Melms; Wei-Hua Chiu; Joachim N Goebel; Tasnim Chakroun; Thomas Koeglsperger; Wolfgang H Oertel; Thomas W Rösler; Marc Bickle; Günter U Höglinger
Journal:  Sci Rep       Date:  2017-09-13       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.